Pernix Therapeutics, Pozen, GlaxoSmithKline, CPP Investment Board deal

By WIR Staff | May 19, 2014 | 7:00 AM GMT

Pernix acquired from GlaxoSmithKline the U.S. rights to Treximet sumatriptan/naproxen to treat migraines for an upfront payment of $250 million. GSK had U.S. marketing rights from Pozen

Read the full 272 word article

How to gain access

Continue reading with a
two-week free trial.